Purpose of Review We aim to summarise the available evidence on systemic therapies for advanced anal cancer. Recent Findings There is no universal consensus on the management of this condition and the prognosis remains poor. Nevertheless, significant progress has been recently made including completion of the first, ever-conducted, randomised trial in the first-line setting, investigation of immunotherapy in the refractory setting and use of comprehensive genomic profiling for a better molecular characterisation of this disease and the identification of novel potential targets. Summary The combination of a platinum agent and a fluoropyrimidine is generally considered the standard first-line treatment. Other cytotoxic agents, especially docetaxel and paclitaxel, have shown activity in both the chemotherapy-naive and chemo- refractory setting and are currently being investigated in clinical trials. Finally, further to the promising results of early clinical trials, immunotherapy with checkpoint inhibitors (i.e. nivolumab and pembrolizumab) is likely to become a standard second-line treatment option. . . . . . . . Keywords Advanced anal cancer Systemic therapy Chemotherapy Cisplatin Carboplatin 5-Fluorouracil Capecitabine . . . . . . . . Paclitaxel Docetaxel Mitomycin Targeted therapy Cetuximab Panitumumab Immunotherapy Pembrolizumab . . . . Nivolumab LY2606368 HPV InterAACT Epitopes-HPV02 Introduction pecially genotypes
Current Oncology Reports – Springer Journals
Published: May 4, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud